Related Experiment Video
Updated: Jul 11, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Community analysis of large-scale molecular dynamics simulations elucidated dynamics-driven allostery in tyrosine
Nastazia Lesgidou1, Metaxia Vlassi1
1National Center for Scientific Research "Demokritos", Institute of Biosciences & Applications, Athens, Greece.
Abstract:
TYK2 is a nonreceptor tyrosine kinase, member of the Janus kinases (JAK), with a central role in several diseases, including cancer. The JAKs' catalytic domains (KD) are highly conserved, yet the isolated TYK2-KD exhibits unique specificities. In a previous work, using molecular dynamics (MD) simulations of a catalytically impaired TYK2-KD variant (P1104A) we found that this amino acid change of its JAK-characteristic insert (αFG), acts at the dynamics level. Given that structural dynamics is key to the allosteric activation of protein kinases, in this study we applied a long-scale MD simulation and investigated an active TYK2-KD form in the presence of adenosine 5'-triphosphate and one magnesium ion that represents a dynamic and crucial step of the catalytic cycle, in other protein kinases. Community analysis of the MD trajectory shed light, for the first time, on the dynamic profile and dynamics-driven allosteric communications within the TYK2-KD during activation and revealed that αFG and amino acids P1104, P1105, and I1112 in particular, hold a pivotal role and act synergistically with a dynamically coupled communication network of amino acids serving intra-KD signaling for allosteric regulation of TYK2 activity. Corroborating our findings, most of the identified amino acids are associated with cancer-related missense/splice-site mutations of the Tyk2 gene. We propose that the conformational dynamics at this step of the catalytic cycle, coordinated by αFG, underlie TYK2-unique substrate recognition and account for its distinct specificity. In total, this work adds to knowledge towards an in-depth understanding of TYK2 activation and may be valuable towards a rational design of allosteric TYK2-specific inhibitors.
Insights
This study reveals how the dynamics of TYK2 kinase activation, particularly the alphaFG region, are crucial for its unique function and cancer-related mutations. Understanding these dynamics aids in designing specific TYK2 inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- TYK2 (Tyrosine Kinase 2) is a Janus kinase (JAK) implicated in various diseases, including cancer.
- While JAK catalytic domains (KD) are conserved, TYK2-KD shows unique specificities.
- Previous work indicated that mutations in TYK2-KD's alphaFG insert affect its dynamics.
Purpose of the Study:
- To investigate the dynamic profile and allosteric communications within the active TYK2-KD during ATP binding.
- To elucidate the role of specific amino acids and the alphaFG region in TYK2 kinase activation dynamics.
- To understand the structural basis for TYK2's unique substrate recognition and specificity.
Main Methods:
- Long-scale molecular dynamics (MD) simulations of active TYK2-KD with ATP and Mg2+.
- Community analysis of the MD trajectory to identify dynamic profiles and allosteric communication networks.
- Correlating identified amino acid residues with known cancer-related mutations in Tyk2.
Main Results:
- The study identified a dynamic profile and allosteric communication network within TYK2-KD during activation.
- The alphaFG insert, along with residues P1104, P1105, and I1112, plays a pivotal role in intra-KD signaling for allosteric regulation.
- A significant number of identified key residues are associated with cancer-related mutations in the Tyk2 gene.
Conclusions:
- Conformational dynamics, coordinated by the alphaFG region, are fundamental to TYK2 activation and unique substrate specificity.
- The identified dynamic network provides insights into TYK2's distinct role in cellular signaling.
- This research supports the rational design of allosteric TYK2-specific inhibitors for therapeutic applications.

